

This form must be completed and submitted along with the word version of every policy or guideline to be uploaded to the Policies and Guidelines page of the Intranet.

Email: policies@waikatodhb.health.nz

<input checked="" type="checkbox"/> New / Revised version issued for three years Use for all new policies and guidelines Use for all policies and guidelines having full three-yearly review	<input type="checkbox"/> Amended version reissued with minor change DO NOT use for expired policies or guidelines This option will not alter the expiry date of the policy or guideline
---	---

Document Title:	Prednisolone for neonates		
Reference No:	6637	Version No:	V1
Document Type: <small>(E.g. Policy, Procedure, Drug Guideline, etc)</small>	Neonatal Medicine Guideline	Scope:	<input type="checkbox"/> Health NZ Waikato <input checked="" type="checkbox"/> Clinical management / service specific
Effective Date:	October 2024	Publish on the Internet?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> After next full review

Reason for Re-issue with Minor Changes <small>(Amended versions only)</small>	
---	--

Implementation Plan <small>How you are going to ensure your policy or guideline is implemented across the organisation or service area? Implementation Plans</small>	
--	--

General Disposal Authority <small>This covers how long the document must be retained and if / when it can be destroyed DHB GDA (Policies and Guidelines)</small>	<input checked="" type="checkbox"/> Significant (sent to Archives NZ)	<input type="checkbox"/> Minor (ongoing) (Destroyed 7 years after being superceded)
--	--	--

AUTHORISATION	Name (Please Print)	Position Title (Please Print)	Date	Signature
Document Authoriser:	John Barnard	Chair M&T Committee		
Document Owner:	Jutta van den Boom	Clinical Director NICU		
Document Facilitator:	Kerrie Knox	Pharmacist		

Prednisolone for neonates

BRIEF ADMINISTRATION GUIDE

For detailed information refer to [The Australasian Neonatal Medicines Formulary \(ANMF\) prednisolone guideline](#)



Note: Shaded text indicates where Health NZ Waikato practice differs from ANMF

1. Medicine

1.1. Indications

Moderate to severe chronic lung disease in term corrected infants (>36/40 weeks corrected gestation). Consider if:

- $FiO_2 > 0.4$, or ventilator dependent, or MAP (mean airway pressure) or PEEP > 8cm H₂O
- At least 2 previous dexamethasone courses
- Significant pulmonary hypertension ruled out (Echo)
- Airway issues ruled out (clinically or ENT laryngo-tracheo-bronchoscopy)
- Respiratory consult +/- initiated

1.2. Route and Presentation

Oral

Supplied as:

- Prednisolone oral liquid 5 mg/mL, 30 mL bottle

1.3. Dose

0.25 - 2 mg/kg/day, in daily or divided doses, with a typical regime as follows:

- 2 mg/kg/day for one week, then
- 1 mg/kg/day for one week, then
- 0.5 mg/kg/day for one week, then
- 0.5 mg/kg/day every second day for 3 doses, then stop.

Note:

- Dosing regime and weaning is at the discretion of the Neonatologist and is based primarily on the infant's respiratory status
- Round dose to something sensible for administration (d/w Neonatologist). Continue to give the same dose without increasing for weight

2. Preparation and Administration

2.1. Compatible fluids

N/a

2.2. Administration Method

- Shake bottle well before withdrawing the dose
- Withdraw dose using an oral syringe
- Administer in the morning (for once daily doses) with food or milk

2.3. Monitoring

- Blood pressure, weight, height, growth, electrolytes, blood glucose levels, signs of infection.

2.4. Storage and Stability

- Store at room temperature (at or below 30°C) for both unopened and opened bottle
- Discard 4 weeks after opening

2.5. Competency for Administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Health NZ Waikato Generic Medicine skills verification.

Prednisolone for neonates

3. References

- New Zealand Formulary for Children (NZFC), version 141, 2024. Prednisolone (systemic). Available from: https://www.nzfchildren.org.nz/nzfc_3846
- Canterbury DHB Neonatal Services. Prednisolone Drug Information sheet, available from <https://edu.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets/Documents/Prednisolone.pdf>
- Queensland Health Prednisolone neonatal guideline. Accessed via www.health.qld.gov.au/_data/assets/pdf_file/0035/1137788/nmq-prednisolone.pdf
- Datasheet for Redipred. Pharmacy Retailing (NZ) Ltd, October 2022. Accessed via Medsafe www.medsafe.govt.nz/profs/datasheet/r/Redipredoralliq.pdf
- Linafelter A et al. Extended course of prednisolone in infants with severe bronchopulmonary dysplasia. Early Human Development 136 (2019) 1-6.
- Bhandari A et al. Effect of a Short Course of Prednisolone in Infants With Oxygen-Dependent Bronchopulmonary Dysplasia. Pediatrics Vol 121 (2) Feb 2008, e344-349.
- Australasian Neonatal Medication Formulary, prednisolone monograph 2024. Accessed via www.anmfonline.org/wp-content/uploads/2024/03/Prednisolone_ANMFv1.0_20240711.pdf

Document Ownership

Document Authorisor:	John Barnard	Chair Medicines & Therapeutics Committee
Document Authorisor:	Jutta van den Boom	Head of Department - Neonatal Intensive Care Unit
Document Facilitator:	Kerrie Knox	Pharmacist

Disclaimer: This document has been developed for use specifically by staff at the former Waikato District Health Board. Caution should be exercised before use outside this district. Any reliance on the information contained herein by any third party is at their own risk and Health New Zealand | Te Whatu Ora assumes no responsibility whatsoever for any issues arising as a result of such reliance.